Luminex Corporation has announced that its xTAG® Technology has been selected for use in enhancing the processing speed and capacity of Assurex Health's patented GeneSight® tests.
Healthcare providers use GeneSight to help patients affected by neuropsychiatric conditions including depression, posttraumatic stress disorder (PTSD), anxiety, bipolar disorder, schizophrenia, ADHD, and acute and chronic pain.
This agreement incorporates Luminex's open-architecture xTAG Technology into the GeneSight testing process and enables large numbers of tests to be conducted and analyzed quickly, cost-effectively, and accurately.
"With our unique portfolio of pharmacogenetics assays, flexible platforms, and support, Luminex is delighted to be selected as the partner of choice by Assurex Health," said Homi Shamir, President and CEO of Luminex. "Assurex Health is at the forefront of the fast-growing field of personalized medicine, and we are excited that our technology will be a part of this solution. We look forward to partnering with Assurex Health in their goal of helping clinicians determine the right therapeutics for their patients."
"Luminex's highly sensitive xTAG Technology will improve our workflow efficiency without increasing cost," said Donald R. Wright, Executive Vice President and Chief Operating Officer, Assurex Health. "In addition, the flexibility of the Luminex platform will allow us to add new biomarkers as our needs continue to expand."
Pharmacogenetics Innovation at Luminex
Luminex launched its first test to aid in personalized medicine in 2010. Since that time, Luminex has received Health Canada Approval, U.S. FDA clearance, and European clearance for its xTAG CYP2D6 Kit v3 and xTAG CYP2C19 Kit v3 assays. Luminex is a member of the Personalized Medicine Coalition.